Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma

Japanese Journal of Clinical Oncology

Volumn 42, Issue 5, 2012, Pages 442-446

  Mizuno, Ryuichi ^a   Asano, Koichiro ^a   Mikami, Shuji ^b   Nagata, Hirohiko ^a   Kaneko, Gou ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Everolimus; Interstitial lung disease; Renal cell carcinoma

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; EVEROLIMUS; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB; SURFACTANT PROTEIN D;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG BIOPSY; LUNG DISEASE; LUNG LAVAGE; LYMPHOCYTOSIS; MALE; METASTASIS; STEROID THERAPY; THORAX RADIOGRAPHY;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; KIDNEY NEOPLASMS; L-LACTATE DEHYDROGENASE; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-1; PULMONARY SURFACTANTS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84860444651     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys033     Document Type: Article

References (16)

1. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115:2438-46.
2. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
3. Champion L, Stern M, Israel-Biet D, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006;144:505-9.
4. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215-20.
5. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010;137:456-9.
6. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000;343:225-6.
7. Hamour IM, Mittal TK, Bell AD, Banner NR. Reversible sirolimus-associated pneumonitis after heart transplantation. J Heart Lung Transplant 2006;25:241-4.
8. Exposito V, de Prada JA, Gomez-Roman JJ, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008;27:797-800.
9. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59:526-40.
10. Tsukamoto T, Shinohara N, Tsuchiya N, et al. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011;41: 17-24.
11. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-62.
12. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91(Suppl 2):S18-23.
13. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
14. Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med 1999;159:646-78.
15. Oyama T, Kohno N, Yokoyama A, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung 1997;175:379-85.
16. Ohtsuki Y, Fujita J, Hachisuka Y, et al. Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia. Med Mol Morphol 2007;40:198-202.